Boston Scientific (BSX) Cost of Revenue (2009 - 2026)

Boston Scientific has disclosed Cost of Revenue across 18 years of filings, most recently posting $1.6 billion for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $1.6 billion, up 11257.14% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 billion (up 139.88% YoY), and the FY2025 annual result was $6.2 billion, up 18751.52% from the prior year.
• Cost of Revenue came in at $1.6 billion for Q1 2026 at Boston Scientific, down from $1.6 billion in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $4.3 billion in Q4 2023 to a low of -$2.9 billion in Q4 2022.
• The 5-year median for Cost of Revenue is $955.0 million (2022), against an average of $656.8 million.
• Across the five-year window, Cost of Revenue slumped 398.15% in 2022 and soared 17766.67% in 2025, its largest moves.
• Boston Scientific's Cost of Revenue stood at -$2.9 billion in 2022, then soared by 248.72% to $4.3 billion in 2023, then sank by 99.79% to $9.0 million in 2024, then jumped by 17766.67% to $1.6 billion in 2025, then dropped by 1.12% to $1.6 billion in 2026.
• The last three Cost of Revenue figures came in at $1.6 billion (Q1 2026), $1.6 billion (Q4 2025), and $12.0 million (Q3 2025), per Business Quant data.